The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 1 of the 4 sources its claims cite were checked for support.
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Open accessAbstract
Abstract Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. Design Systematic review and network meta-analysis. Data sources PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from database inception to 19 August 2023. Eligibility criteria for selecting studies Eligible randomised controlled trials enrolled adults with type 2 diabetes who received GLP-1RA treatments and compared effects with placebo or any GLP-1RA drug, with a follow-up duration of at least 12 weeks. Trials with a crossover design, non-inferiority studies comparing GLP-1RA and other drug classes without a placebo group, using withdrawn drugs, and non-English studies were deemed ineligible. Results 76 eligible trials involving 15 GLP-1RA drugs and 39 246 participants were included in this network meta-analysis; all subsequent estimates refer to the comparison with placebo. All 15 GLP-1RAs effectively lowered haemoglobin A 1c and fasting plasma glucose concentrations. Tirzepatide induced the largest reduction of haemoglobin A 1c concentrations (mean difference −2.10% (95% confidence interval −2.47% to −1.74%), surface under the cumulative ranking curve 94.2%; high confidence of evidence), and fasting plasma glucose concentrations (−3.12 mmol/L (−3.59 to −2.66), 97.2%; high confidence), and proved the most effective GLP-1RA drug for glycaemic control. Furthermore, GLP-1RAs were shown to have strong benefits to weight management for patients with type 2 diabetes. CagriSema (semaglutide with cagrilintide) resulted in the highest weight loss (mean difference −14.03 kg (95% confidence interval −17.05 to −11.00); high confidence of evidence), followed by tirzepatide (−8.47 kg (−9.68 to −7.26); high confidence). Semaglutide was effective in lowering the concentration of low density lipoprotein (−0.16 mmol/L (−0.30 to −0.02)) and total cholesterol (−0.48 mmol/L (−0.84 to −0.11)). Moreover, this study also raises awareness of gastrointestinal adverse events induced by GLP-1RAs, and concerns about safety are especially warranted for high dose administration. Conclusions GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A 1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss. The results prompt safety concerns for GLP-1RAs, especially with high dose administration, regarding gastrointestinal adverse events. Systematic review registration PROSPERO CRD42022342845.
Overview
CoChat Summary
## TL;DR
This systematic review and network meta-analysis of 76 randomized controlled trials (39,246 participants) compared 15 GLP-1 receptor agonists for type 2 diabetes. Tirzepatide ranked best for glycaemic control, CagriSema for weight loss, and several drugs increased gastrointestinal adverse events.
## Key findings
- Across 76 trials involving 39,246 adults, all 15 GLP-1RAs significantly reduced HbA1c and fasting plasma glucose versus placebo.
- Tirzepatide had the largest HbA1c reduction: mean difference −2.10% (95% CI −2.47% to −1.74%) and fasting plasma glucose reduction: −3.12 mmol/L (−3.59 to −2.66), both with high confidence of evidence.
- CagriSema produced the greatest weight loss: −14.03 kg (95% CI −17.05 to −11.00); tirzepatide was next: −8.47 kg (−9.68 to −7.26).
- Semaglutide lowered low-density lipoprotein by −0.16 mmol/L (−0.30 to −0.02) and total cholesterol by −0.48 mmol/L (−0.84 to −0.11); PEG-loxenatide increased HDL by 0.16 mmol/L (0.00 to 0.31).
## Methods
- Systematic review and network meta-analysis of randomized controlled trials, registered in PROSPERO (CRD42022342845) and reported under PRISMA/PRISMA-NMA.
- Searched PubMed, Web of Science, CENTRAL, and Embase from inception to 19 August 2023, plus conference websites, ClinicalTrials.gov, references, and prior reviews; included English-language peer-reviewed RCTs in adults with type 2 diabetes, follow-up ≥12 weeks.
- Used frequentist random-effects network meta-analysis in Stata, with SUCRA rankings, node-splitting/design-treatment interaction for consistency, CINeMA and RoB 2 for evidence quality/bias, and meta-regression/subgroup analyses by dose, follow-up, age, diabetes duration, and background treatment.
## Limitations
- The paper states that included trials varied in population characteristics and follow-up durations, which may have led to imprecise effect estimates.
- The paper states that participants had little control over diet and exercise, which may have influenced blood glucose and body weight.
- The paper states that some trials did not provide enough information to assess randomization, allocation concealment, or blinding, and some drugs had few studies, so subgroup and comparative results should be interpreted cautiously.
- Evident from the text: the review excluded non-English studies, conference abstracts, crossover trials, and non-inferiority studies without a placebo arm, so the evidence base may be narrower than all available GLP-1RA trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
1 Valid · 0 Not valid · 1 Not checked · 41 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“GLP-1RAs have been shown to greatly reduce the body weight of obese people with type 2 diabetes.8 14”
§ Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis > Introduction
What the sources say
- Supportedcites [8] source
The Research in context section reports that the GLP-1 receptor agonists liraglutide and semaglutide produced placebo-adjusted body-weight reductions of 4.0%–6.2% in people with overweight or obesity and type 2 diabetes. This supports the citing sentence's broad claim; the section also distinguishes these drugs from tirzepatide, a dual GIP and GLP-1 receptor agonist. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [14] source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 15 GLP-1RA drugs showed significant efficacy in reducing HbA1c levels compared with placebo in adults with type 2 diabetes (fig 2, fig 3).”
§ Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis > Results > Glycaemic control
plainstates a causen = 343- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Evaluated by fasting blood glucose, the network meta-analysis enrolled 47 randomised controlled trials with 17 163 subjects, confirming the placebo controlled effectiveness of all the 15 GLP-1RAs (fig 4, fig 5).”
§ Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis > Results > Glycaemic control
boostedstates a causen = 163- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The efficacy of tirzepatide in lowering concentrations of HbA1c and fasting blood glucose, and lowering body weight was directly proportional to the length of follow-up duration (appendix 15).”
§ Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis > Results > Subgroup analyses
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“followed by tirzepatide (−8.47 kg (−9.68 to −7.26); high confidence).”
§ Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 43 claims and every source verdict.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, GLP‐1RA treatments showed over twice the odds of discontinuation due to adverse events compared with placebo. 27”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“According to recent studies, tirzepatide, orforglipron, semaglutide, liraglutide, and exenatide were positively associated with diarrhea when compared with placebo, while liraglutide was associated with diarrhea when compared with exenatide and placebo [51, 53, 56].”
From Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis (2025) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nausea was the most frequently reported symptom, besides vomiting and diarrhea, findings consistent with prior research in diabetic populations [51–56].”
From Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis (2025) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The benefits of this form of therapy to treat T2DM include 1) delayed gastric emptying, and 2) inhibiting the production of glucagon from pancreatic α- cells (71–73).”
From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [73]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a meta‐analysis of 76 RCTs in T2D, liraglutide, semaglutide and tirzepatide were all associated with significantly increased ORs of nausea, vomiting and diarrhoea. 27”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [27]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935
Variance imputation for overviews of clinical trials with continuous response
Follmann, D., Elliott, P., Suh, I., & Cutler, J. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90054-q · Cited by 1,385
Cited by
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y. Q., Sattar, N., Dalakoti, M., et al. (2025) · Diabetes Care · doi:10.2337/dc24-1678 · Cited by 208
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
“Previous systematic reviews and meta-analyses of RCTs have examined the ef fi cacy and safety of GLP-1 RAs for weight loss in people with overweight or obesity, both with diabetes (46 – 48) and without diabetes (1, 49 – 51).”
Mitochondrial metabolic reprogramming in diabetic kidney disease
Fan, X., Yang, M., Lang, Y., Lu, S., Kong, Z., Gao, Y., Shen, N., Zhang, D., & Lv, Z. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06833-0 · Cited by 173
Metadata
- Authors
- Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S.
- Affiliations
- Beijing University of Chinese Medicine (CN)
- University of Chicago (US)
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2024-01-29
- Volume
- 384
- Pages
- e076410
- ISSN
- 1756-1833 (ISSN-L)
- PMC
- PMC10823535
- OpenAlex
- W4391309422
- Cited by
- 558
- References
- 42
- Citations by year
- 2026: 196 · 2025: 259 · 2024: 103
- FWCI
- 32.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMJ (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Natural Science Foundation of China (82274379)
- Beijing University of Chinese Medicine
- Fundamental Research Funds for the Central Universities
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, lipid profile, HbA1c, fasting blood glucose, tirzepatide, semaglutide, cagrilintide, LDL cholesterol, triglycerides, drug safety, drug efficacy comparison, weight management
- MeSH terms
- Glycemic Control, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Weight Loss, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1136/bmj-2023-076410
- The paper
- Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024). Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. https://doi.org/10.1136/bmj-2023-076410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.